Novartis Announces New Strategy To Provide Innovative Medicines To More Patients In Sub-Saharan Africa

Must Read

List of United Bank for Africa (UBA) Sort Codes & Branches (with addresses) in Nigeria

The sort code is a number that usually identifies both the bank and the branch where an account is held. The sort...

List of First Bank of Nigeria Sort Codes in Nigeria

The sort code is a number that usually identifies both the bank and the branch where an account is held. The sort...

How To Block Your Bank Account And SIM Card In Case Of Emergency

Losing your phone and wallet or having them stolen can be very frustrating. However, in case that happens to...
- Advertisement -

The strategy is aligned with the Novartis Access Principles, which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally; a newly formed sub-Saharan Africa unit will deploy innovative approaches to increase patient reach across the full income pyramid. Novartis is building on its established activities in malaria, cancer, sickle cell and cardiovascular diseases as well as proven social business models on the continent; a quarter of the global disease burden is located in Africa, but only 3% of the world’s health workers are based on the continent and the share of the world’s health expenditure for Africa is below 1%.1.

Novartis announced today a new strategy to broaden patient reach and availability of its portfolio of medicines in sub-Saharan Africa (SSA), which is home to the largest underserved patient population in the world. Novartis also aspires to be the partner of choice for governments and NGOs to strengthen healthcare systems across Africa.

“We are deeply committed to improving access to medicines around the world,” says Vas

Narasimhan, CEO of Novartis. “Building on our longstanding efforts to improving health in Africa, including on malaria and sickle cell disease, we’re taking a comprehensive approach to ensuring patients in sub-Saharan Africa, regardless of income, have access to our portfolio of medicines.” 

- Advertisement -

A quarter of the global disease burden weighs on Africa, but only 3% of the world’s health workers are based on the continent and the share of the world’s health expenditure for Africa is below 1%. Health systems frequently have to rely on NGOs and external donors to fund and provide services for the largest underserved patient population in the world.

As part of the new strategy, Novartis will pivot the current organizational focus in SSA from financial metrics such as sales performance and profits to metrics that drive access to innovative medicines and strengthen health systems in the region. A new organizational unit will bring together the expertise and portfolio of our Sandoz Division, the Novartis

Read Also:  UNILAG Stands Still For The Itel Mobile Takeover, rolls out gift items (Photos)

Pharmaceuticals and Oncology business units comprising our Innovative Medicines Division and Novartis Social Business. Racey Muchilwa is appointed Head of Global Health SSA, contributing her strong knowledge of the healthcare system and patient needs in the region.  The SSA unit aims to maximize patient reach across the full income pyramid by focusing on tiered pricing models, competitiveness in tenders and scaling social business models as well as affordability strategies. Novartis also will work to increase its clinical trial capabilities and accelerate regulatory and administrative processes in the region to shorten the time between the development, approval and ultimately access to new medicines for patients across SSA.

“I feel honoured to lead our talented team in executing our new strategy. Our aspiration is to be the leading healthcare partner in sub-Saharan Africa and work with NGOs and governments to strengthen health systems,” says Racey Muchilwa, Head of Global Health SSA. “We aim to harness the power of digital and new technologies, to maximize the impact we can have on the health of people in sub-Saharan Africa where the population is expected to double by 2050 to 2.2 billion.” 

- Advertisement -

Novartis has a long-standing commitment to helping improve the health of people in Africa. This includes communicable diseases such as malaria and leprosy as well as non-communicable diseases such as sickle cell disease (SCD), cardiovascular disease and cancer. Novartis has contributed nearly 900 million courses of malaria treatment at no-profit to patients in malaria-endemic countries, including more than 380 million doses of our pediatric formulation.  Novartis is also pioneering research and development with clinical trials, utilizing novel biologic molecules and deploying new technologies to provide the benefits of cutting-edge innovation to the region. Most recently, the company announced a broad public-private partnership with the government of Ghana to tackle sickle cell disease, including access to available medicine, clinical research and use of digital technologies to achieve global standards of care.

- Advertisement -
Novartis Announces New Strategy To Provide Innovative Medicines To More Patients In Sub-Saharan Africa - Brand SpurNovartis Announces New Strategy To Provide Innovative Medicines To More Patients In Sub-Saharan Africa - Brand Spur

Subscribe to BrandSpur Ng

Subscribe for latest updates. Signup to best of brands and business news, informed analysis and opinions among others that can propel you, your business or brand to greater heights.

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Novartis Announces New Strategy To Provide Innovative Medicines To More Patients In Sub-Saharan Africa - Brand SpurNovartis Announces New Strategy To Provide Innovative Medicines To More Patients In Sub-Saharan Africa - Brand Spur

Latest News

Next Meats, Purveyor of the World’s First Plant-based Yakiniku Meats, Is Now in Singapore

The Tokyo-based startup makes its debut in the alt-protein hotspot of Singapore

 

  • Next Meats has collaborated with Aburi-EN to deliver two new meal sets
  • Made with soybean proteins, the Kalbi contains no chemical additives or animal ingredients


SINGAPORE - Media OutReach - 14 April 2021 - Next Meats, a purveyor of the world's first plant-based yakiniku meats, is making its debut in the alternative protein hotspot, Singapore! The Japanese alternative meat company has collaborated this time with popular Japanese restaurant Aburi-EN, which will offer two types of set meals using the NEXT Kalbi (boneless short rib) for the very first time. Made largely from soy proteins, the NEXT Kalbi contains double the amount of protein and half the fats than that of regular meat and even more, it does not contain any chemical additives or cholesterol due to its lack of animal ingredients. Now, Singaporeans can enjoy yakiniku without the guilt!


Novartis Announces New Strategy To Provide Innovative Medicines To More Patients In Sub-Saharan Africa - Brand Spur

From left to right: Premium Kalbi Don Set and Stamina Teishouku Set

The two new menus available at Aburi-EN are the Kalbi Don Set (S$13.80) and the Stamina Teishoku (S$15.80) — which are available for a limited time only. Next Meats has specifically chosen to work with Aburi-EN as they are a Japanese grilled-meat specialist. The two menus are the culmination of many months of research and development, and they will also be Aburi-EN's first-ever plant-based dishes.


Novartis Announces New Strategy To Provide Innovative Medicines To More Patients In Sub-Saharan Africa - Brand Spur

For the Kalbi Don Set, Next Meat's Kalbi is grilled and served atop a bowl of fragrant Japanese steamed rice. Equally indulgent, the Stamina Teishoku features the Kalbi stir-fried with cabbage along with egg imported from Okinawa. The meat is then served with fragrant Japanese steamed rice, salad, pickles and miso soup. For both dishes, the meats are glazed with a special homemade sauce that packs an irresistible umami punch.

Both the Kalbi Don Set and Stamina Teishoku will be available at all Aburi-EN stores from April to July 2021.

An advocate of sustainable food production and better food security

The NEXT Kalbi is one of Next Meats' innovative offerings, which includes other plant-based delicacies such as the NEXT burger and NEXT gyudon (beef bowl). The company champions the importance of saving the planet and humanity through reducing the emission of greenhouse gases (which is produced from meat consumption and animal agriculture) and utilizing biotechnology to combat protein deficiency.

Through extensive research and development, Next Meats has culminated the knowhow on using molecular binding to mould vegetable proteins from powder. Buoyed by state-of-the-art, proprietary technologies, the company has successfully created vegan substitutes that replicate the texture of real meat.

About Next Meats

Hailing from Tokyo, Next Meats is a food-tech venture company that specialises in the research and development of Japanese-style alternative meat products. Its journey of product development began in 2017, and the company was officially established in 2020. Its portfolio of products includes plant-based burger patties, gyudon and yakiniku meats.

Social Media for Next Meats

Facebook: /nextmeats.singapore

Instagram: @nextmeats_singapore

Hashtags: #nextmeats #nextmeats_sg #japaneseplantbased


About Aburi-EN

Aburi-EN is Singapore's leading Japanese Grill restaurant chain, best known for delicious high quality grilled donburi bowls. Signature dishes include the Premium Buta Don with grilled chestnut-fed pork, Wagyu Karubi Don, and the Wagyu Stamina Don, made using A4/A5 Miyazaki Wagyu, which has won Japan's "National Wagyu Award" for 3 consecutive years, among many others. The homemade sauces give the meats and dishes an extra umami-ness. Aburi-EN is also known for affordable highballs and Japanese sours, which pair perfectly with the Aburi dishes.

Social Media for Aburi-EN

Facebook: /aburiensg

Instagram: @aburien.sg

Hashtags: #aburiensg #aburiendonburi #aburienjapanesegrill

Outlets

- Isetan Scotts:

350 Orchard Rd, #01-K1 Shaw House, Singapore 238868

- Causeway Point

1 Woodlands Square, #02-09B Causeway Point, Singapore 738099

- Jem

50 Jurong Gateway Rd, #01-04 Jem, Singapore 608549

- Vivo City

1 Harbourfront Walk, #01-159/160 VivoCity, Singapore 098585

- Novena Square

238 Thomson Rd, #01-89/90, Singapore 307683

- Guoco Tower

1 Wallich St, #B2 - 09, Singapore 078884

- Orchard Central

181 Orchard Central, Central, #01-16 Orchard, 238896

- Suntec City

3 Temasek Blvd, #B1-121 Suntec City Mall, Singapore 038983

- Nex

23 Serangoon Central, #01-63/64/65 Nex, Singapore 556083

Operating Hours

11am – 10pm, Daily

Novartis Announces New Strategy To Provide Innovative Medicines To More Patients In Sub-Saharan Africa - Brand Spur
- Advertisement -
BrandsPur Weekly Cartoons
- Advertisement -Novartis Announces New Strategy To Provide Innovative Medicines To More Patients In Sub-Saharan Africa - Brand SpurNovartis Announces New Strategy To Provide Innovative Medicines To More Patients In Sub-Saharan Africa - Brand Spur